TB-500

Product Specifications

CAS: 77591-33-4

Sequence: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser

Molecular Formula: C₂₁₂H₃₅₀N₅₆O₇₈S

Molecular Mass: 4963.5 Da

Purity: 99%+ (verified by HPLC)

Appearance: White to off-white lyophilized powder

Form: Lyophilized (freeze-dried)

Active Region: LKKTETQ (amino acids 17-23, responsible for actin binding and cell migration)

Storage

TB-500 vials must be stored in a cool, dry place away from direct sunlight. Unreconstituted TB 500 peptide should be kept at -20°C for long-term storage or 2-8°C for short-term storage. Once reconstituted with bacteriostatic water, TB-500 should be refrigerated at 2-8°C and used within 30 days for optimal stability. Do not freeze reconstituted solutions. Always follow proper storage guidelines to maintain product integrity for research applications.

Solubility

TB 500 is freely soluble in bacteriostatic water and sterile saline. Recommended reconstitution concentration is 1-5 mg/mL. Gently swirl the vial after adding solvent. Do not vortex or shake vigorously, as this may damage the peptide structure.

Intended Use

TB-500 is intended for research purposes only and is not approved for human use.

TB 500 Peptide Benefits for Wound Healing and Tissue Repair

• TB-500 is a synthetic version of thymosin beta 4, a protein that plays a central role in cell migration, angiogenesis, and tissue regeneration. The active region LKKTETQ binds to actin, promoting the movement of cells toward injury sites for faster repair.
• In preclinical wound models, thymosin beta 4 treatment increased reepithelialization by 42% at day 4 and up to 61% at day 7 compared to controls. Treated wounds also showed at least 11% greater contraction and significantly increased collagen deposition.
• TB 500 stimulates keratinocyte migration at concentrations as low as 10 picograms, demonstrating exceptional potency in activating the cellular mechanisms required for skin repair and wound closure.
• Research also indicates TB-500 reduces scar formation by decreasing the number of myofibroblasts at wound sites, leading to cleaner healing outcomes with less fibrosis in damaged tissue.

What Are the Anti-Inflammatory and Cardioprotective Benefits of TB-500?

• Studies show TB 500 possesses strong anti-inflammatory properties, reducing inflammatory cytokines at injury sites. This makes thymosin beta 4 a key focus in research on recovery from muscle, tendon, and ligament injuries.
• In cardiac research, a combination of thymosin beta 4 and prothymosin alpha significantly enhanced cardiomyocyte proliferation in both cultured cells and living mice, creating a supportive environment that reduced infarct size, cardiac fibrosis, and cell death while improving overall heart function.
• TB-500 side effects in preclinical studies have been minimal. The peptide is well tolerated across multiple animal models, supporting its safety profile for continued research applications.

Does TB-500 Promote Hair Growth and Stem Cell Activation?

• Thymosin beta 4 is a natural modulator of hair follicle development. In mouse studies, overexpressing mice showed full hair regrowth in 11 days compared to 16 days in knockout mice, with significantly elevated hair shaft counts and follicle density.
• TB 500 hair growth effects work through stimulation of VEGF expression (increased 2.33-fold in treated subjects) and activation of the P38/ERK/AKT signaling pathways, which drive angiogenesis around hair follicles and promote stem cell migration to the follicle base.
• Research confirms TB-500 activates quiescent stem and progenitor cells, promoting their migration, differentiation, and integration into damaged tissue. This mechanism underlies TB 500 benefits across wound healing, hair growth, and organ repair.

TB 500 Dosage for Research

The TB 500 dosage used in preclinical research varies depending on the study design, animal model, and target tissue. Common dosing protocols in the published literature include:

• Topical application: 5-10 micrograms applied directly to wound sites for dermal healing studies.
• Intraperitoneal injection: 6 mg/kg body weight, commonly used in cardiac and systemic tissue repair models.
• Subcutaneous injection: 1-10 mg/kg body weight, used in wound healing and recovery studies. Loading phases of higher doses followed by maintenance dosing are common in longer protocols.

TB-500 dosing frequency in research protocols typically ranges from daily to twice weekly, depending on the injury model. The TB 500 half life in circulation is relatively short, which informs the frequency of administration in sustained research protocols.

Research Protocol Notes

TB-500 is supplied as a lyophilized (freeze-dried) powder to ensure stability during transport. For experimental protocols, the peptide must be reconstituted using a sterile solvent, most commonly bacteriostatic water or sterile saline. Researchers must ensure the slow, deliberate introduction of the diluent down the side of the vial to prevent damaging the fragile peptide bonds. TB 500 peptide is frequently studied alongside BPC-157 for complementary tissue repair mechanisms.